Skip to main content
Premium Trial:

Request an Annual Quote

Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test

NEW YORK – Cancer diagnostics firm Oncocyte said Wednesday that the US Department of Veterans Affairs has awarded it a Federal Supply Schedule contract for its DetermaRx test, a prognostic assay to aid treatment decisions after lung cancer removal surgery.

The five-year contract will pay for use of the test in early-stage lung cancer patients among the VA's enrolled population of over 9 million. The order lists the contract's total value at almost $3 million.

"Veterans and their families treated at VA and Military Health System medical centers will now have access to our lung cancer test, which informs timely, life-saving treatment decisions following surgery," Oncocyte CEO Ron Andrews said in a statement.

DetermaRx is a 14-gene, PCR-based gene expression assay, performed on tissue samples, that identifies patients at high risk of recurrence following surgery who may benefit from adjuvant drug treatment to eliminate residual cancer cells. Oncocyte has also found in studies that patients whose test results indicate low risk have a 94 percent survival rate without adjuvant chemotherapy treatment, suggesting that this population could avoid the expense and side effects associated with treatment and instead undergo surveillance.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.